Ionis Pharmaceuticals, Inc.
IONS
$75.83
$0.450.60%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 21.03% | 29.74% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 21.03% | 29.74% | |||
| Cost of Revenue | -25.89% | 30.67% | |||
| Gross Profit | 139.08% | -32.98% | |||
| SG&A Expenses | 15.50% | 34.48% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -12.99% | 31.84% | |||
| Operating Income | 45.25% | -33.88% | |||
| Income Before Tax | 59.50% | -77.51% | |||
| Income Tax Expenses | -85.25% | 593.90% | |||
| Earnings from Continuing Operations | 59.66% | -78.37% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 59.66% | -78.37% | |||
| EBIT | 45.25% | -33.88% | |||
| EBITDA | 46.11% | -33.86% | |||
| EPS Basic | 60.37% | -75.90% | |||
| Normalized Basic EPS | 46.84% | -32.29% | |||
| EPS Diluted | 60.37% | -75.90% | |||
| Normalized Diluted EPS | 46.84% | -32.29% | |||
| Average Basic Shares Outstanding | 1.77% | 1.40% | |||
| Average Diluted Shares Outstanding | 1.77% | 1.40% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||